RxDoctor Payments Data

John Midturi, DO

Infectious Disease · Temple, TXNPI 1932169455

Payments from drug & device makers

$953in general payments, 2019–2025

Across 24 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$175
  • Viiv Healthcare Company$173
  • Ferring Pharmaceuticals Inc.$122
  • Melinta Therapeutics, LLC$109
  • Shionogi Inc$106
  • Astellas Pharma US Inc$100
  • plus $168 from 4 others

What the payments were for

  • Food & beverage$80484%
  • Education$14916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$953 in reported general payments places this provider in the 55th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$39,200
Medicare patients
132
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala70$289,771
CabenuvaCabotegravir/Rilpivirine32$202,872
JulucaDolutegravir/Rilpivirine42$152,825
OdefseyEmtricitab/Rilpiviri/Tenof Ala33$121,730
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$82,695
TivicayDolutegravir Sodium34$78,126
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$71,025
IsentressRaltegravir Potassium31$65,375
TriumeqAbacavir/Dolutegravir/Lamivudi13$55,136
DovatoDolutegravir Sodium/Lamivudine12$41,365
PrezcobixDarunavir/Cobicistat12$26,647
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)16$11,829
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$11,030
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl12$957
Lamivudine11$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyCabenuva, Juluca, Tivicay, Triumeq, Dovato$173$530,325133 claims
GileadBiktarvy, Genvoya$25$372,46590 claims
MerckIsentress$175$65,37531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →